Prairie Wealth Advisors Inc. Purchases 84 Shares of Johnson & Johnson (NYSE:JNJ)

Prairie Wealth Advisors Inc. raised its position in Johnson & Johnson (NYSE:JNJ) by 2.8% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,061 shares of the company’s stock after purchasing an additional 84 shares during the period. Prairie Wealth Advisors Inc.’s holdings in Johnson & Johnson were worth $443,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Powers Advisory Group LLC lifted its holdings in Johnson & Johnson by 0.6% during the third quarter. Powers Advisory Group LLC now owns 9,489 shares of the company’s stock worth $1,538,000 after acquiring an additional 61 shares during the period. Knuff & Co LLC raised its stake in shares of Johnson & Johnson by 0.7% during the 3rd quarter. Knuff & Co LLC now owns 9,466 shares of the company’s stock worth $1,534,000 after purchasing an additional 64 shares during the period. Vertex Planning Partners LLC grew its position in Johnson & Johnson by 1.3% during the third quarter. Vertex Planning Partners LLC now owns 5,211 shares of the company’s stock valued at $844,000 after buying an additional 65 shares during the period. Freedom Day Solutions LLC increased its holdings in Johnson & Johnson by 1.1% during the third quarter. Freedom Day Solutions LLC now owns 6,269 shares of the company’s stock worth $1,016,000 after buying an additional 66 shares during the last quarter. Finally, Traphagen Investment Advisors LLC raised its position in Johnson & Johnson by 0.6% in the third quarter. Traphagen Investment Advisors LLC now owns 10,483 shares of the company’s stock worth $1,699,000 after acquiring an additional 67 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.7 %

Shares of JNJ opened at $154.22 on Tuesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The company has a market capitalization of $371.31 billion, a P/E ratio of 23.19, a P/E/G ratio of 2.46 and a beta of 0.52. The firm’s 50 day simple moving average is $147.42 and its 200 day simple moving average is $156.08.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same period in the previous year, the firm posted $2.29 EPS. The firm’s revenue was up 5.3% compared to the same quarter last year. Sell-side analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.22%. Johnson & Johnson’s payout ratio is 74.59%.

Analysts Set New Price Targets

Several research firms have recently weighed in on JNJ. Wells Fargo & Company cut their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Bank of America dropped their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a research note on Thursday, January 23rd. Leerink Partners reduced their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Finally, Raymond James dropped their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $170.67.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.